Navigation Links
Par Pharmaceutical Companies Reports Second Quarter 2011 Results
Date:8/3/2011

WOODCLIFF LAKE, N.J., Aug. 3, 2011 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today reported results for the second quarter ended June 30, 2011.

For the second quarter ended June 30, 2011, the Company reported total revenues of $224.2 million, and income from continuing operations of $9.2 million, or $0.25 per diluted share, which included a one-time charge of $27.7 million related to the Company's restructuring of its branded division, Strativa Pharmaceuticals. Excluding this item and a one-time tax charge, adjusted income from continuing operations (non-GAAP measure) was $29.0 million. On an adjusted cash basis (non-GAAP measure), which excludes amortization expenses, income from continuing operations was $30.9 million, or $0.84 per diluted share for the second quarter 2011. (Please see attached reconciliation page.)  This is compared to reported revenues of $255.5 million and adjusted cash basis income from continuing operations of $25.1 million, or $0.71 per diluted share for the same period in 2010.  

For the six months ended June 30, 2011, the Company reported total revenues of $457.1 million and a loss of $99.7 million from continuing operations, or $2.79 per diluted share, as a result of a $190.6 million pre-tax litigation settlement expense in the first quarter and the aforementioned restructuring and tax charges in the second quarter.  On an adjusted cash basis (non-GAAP measure), income from continuing operations was $65.9 million, or $1.80 per diluted share.  This compares to reported revenues of $547.4 million and income from continuing operations of $44.5 million, or $1.26 diluted share, for the same period in 2010.  On an adjusted cash basis, income from continuing operations for the first six months of 2010 was $51.4 million, or $1.46 per diluted share.

The following is a product level discussion of second quarter 2011 results versus the first quarter 2011:

Key Product Sales

  • Metoprolol:  For the quarter ended June 30, 2011, net sales of metoprolol succinate were $63.7 million compared to net sales of $63.4 million in the first quarter 2011. Par Pharmaceutical, the Company's generic drug division, is the authorized generic for all strengths of AstraZeneca's Toprol XL®.

  • Budesonide EC:  Net sales for budesonide EC in the second quarter were $16.4 million.  Par Pharmaceutical launched the product in the second quarter as the authorized generic for AstraZeneca's Entocort® EC.

  • Sumatriptan: Net sales of sumatriptan succinate were $15.3 million in the second quarter 2011 compared to $16.7 million in the first quarter 2011.  Par Pharmaceutical remained the exclusive supplier of generic Imitrex® 4mg and 6mg starter kits and 4mg prefilled cartridges and had one competitor in the 6mg prefilled cartridges throughout the second quarter.

  • Propafenone Hydrochloride ER: Net sales for Propafenone Hydrochloride ER in the second quarter were $13.3 million compared to $22.0 million in the first quarter.  The decrease was driven by customers' non-recurrence of first quarter launch quantities.  Par Pharmaceutical remained the exclusive supplier of generic Rythmol SR® throughout the second quarter.

  • Amlodipine and Benazepril: Net sales for the second quarter 2011 were $12.5 million compared to $18.2 million in the first quarter.  The decrease was driven by customers' non-recurrence of first quarter launch quantities.

  • Meclizine: Net sales for the second quarter were $4.6 million compared to $4.9 million in the previous quarter. The decrease was driven by customer buying patterns.

  • Other Generic Products: For the second quarter 2011, net sales from all other generic products were $76.7 million. This compares to net sales of $84.5 million in the first quarter 2011. The decrease is due to primarily to the voluntary withdrawal of clonidine in the second quarter and the seasonality of hydrocodone/chlorpheniramine.

  • Megace® ES: Net sales were $14.1 million for the second quarter compared to $14.1 million in the first quarter.

  • Nascobal® B12 Nasal Spray: Net sales were $6.3 million for the second quarter compared to $3.9 million in the first quarter.  The increase was due, in part, to a shortage of a competing vitamin B12 intramuscular injection product.

  • Revenues and gross margin for the second quarter 2011 were $224.2 million and $99.0 million, respectively, compared to $233.0 million in net sales and $109.7 million in gross margin during the prior quarter (Q1 2011). The gross margin rate on the Company's consolidated product portfolio decreased to 44.2% versus 47.1% in the first quarter 2011.  The decrease was due primarily to the non-recurrence of the first quarter launches of propafenone and amlodipine/benazepril and the second quarter launch of lower margin budesonide.  2Q 20111Q 2011$%$%Key Par (Generic) Products (1)(2)$   40.7

    32.3%$   50.6

    40.4%All other Par (Generic)43.3

    56.5%42.0

    49.6%Total Par (Generic)$   84.0

    41.5%$   92.6

    44.1%Strativa (Branded) Products$   15.0

    69.1%$   17.1

    73.7%Total (All Products) $   99.0

    44.2%$ 109.7

    47.1%1. Q211 Key Par Products is comprised of Metoprolol, Budesonide EC, Sumatriptan, Propafenone, Amlodipine/benazapril, Meclizine.

    2. Q111 Key Par Products does not include Budesonide EC as it was launched in Q2.Operating ExpensesExcluding the one-time restructuring charge of $27.7 million, total operating expenses decreased during the second quarter of 2011 as compared to the prior quarter as follows:

  • Research and development expenses were $8.1 million in the second quarter of 2011 compared to $10.7 million in the first quarter.  The decrease was due to lower generic development costs.

  • Selling, general and administrative expenses for the second quarter 2011 decreased to $46.2 million compared to $46.9 million in the first quarter of 2011.  The decrease reflects lower employment costs.

  • Cash and cash equivalents and marketable securitiesThe aggregate balance as of June 30, 2011 was approximately $346 million.

    Product and Pipeline UpdateIn July, Strativa Pharmaceuticals returned the U.S. commercialization rights of Zuplenz® to its development partner, MonoSol Rx, as part of the branded division's restructuring announced in June.

    In July, the Company received a notice letter from a generic pharmaceutical manufacturer, advising that it has filed an Abbreviated New Drug Application with the U.S. FDA containing a Paragraph IV certification referencing Megace® ES.   Megace® ES is protected by Elan Pharma International Limited's U.S. Patents 6,592,903 and 7,101,576.  The Company intends, with Elan, to investigate the Paragraph IV certification and ANDA, and to enforce its patents, which expire in 2020 and 2024, respectively, as appropriate.

    Par Pharmaceutical, along with third-party partners, currently has approximately 31 ANDAs pending with the FDA, 13 of which it believes to be first-to-file opportunities.

    Conference CallAccess to the live webcast can be made via the Company's website at www.parpharm.com.

    Dial-in InformationDomestic:

    866-362-4832International:

    617-597-5364Passcode:

    55151925A replay of the conference call will be available for two weeks approximately one hour after the call.  

    Replay InformationDomestic:

    888-286-8010International:

    617-801-6888Passcode:

    90475213Non-GAAP MeasuresPar Pharmaceutical Companies, Inc. ("the Company") believes it prepared its unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) and pursuant to accounting requirements of the Securities and Exchange Commission.  In an effort to provide investors with additional information regarding the Company's results and to provide a meaningful period-over-period comparison of the Company's financial performance, the Company sometimes uses non-GAAP financial measures as defined by the Securities and Exchange Commission.  The differences between the U.S. GAAP and non-GAAP financial measures are reconciled in an attached schedule.  In presenting comparable results, the Company discloses non-GAAP financial measures when it believes such measures will be useful to investors in evaluating the Company's underlying business performance.  Management uses the non-GAAP financial measures to evaluate the Company's financial performance against internal budgets and targets.  In addition, management internally reviews the Company's results excluding the impact of certain items, as it believes that these non-GAAP financial measures are useful for evaluating the Company's core operating results and facilitating comparison across reporting periods.  Importantly, the Company believes non-GAAP financial measures should be considered in addition to, and not in lieu of, U.S. GAAP financial measures.  The Company's non-GAAP financial measures may be different from non-GAAP financial measures used by other companies.

    About Par Pharmaceutical Companies, Inc.Par Pharmaceutical Companies, Inc. is a US-based specialty pharmaceutical company.  Through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, it develops, manufactures and markets higher-barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals. For press release and other company information, visit www.parpharm.com.

    Safe Harbor StatementCertain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein.  Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company's most recent Annual Report on Form 10-K, in other of the Company's filings with the SEC from time to time, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and on general industry and economic conditions.  Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.

    PAR PHARMACEUTICAL COMPANIES, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In Thousands, Except Per Share Data)(Unaudited)Three months endedSix months endedJune 30,June 30,June 30,June 30,2011201020112010Revenues:Net product sales

    $215,018$248,739$435,807$537,017Other product related revenues

    9,1706,73521,33310,389Total revenues

    224,188255,474457,140547,406Cost of goods sold

    125,162164,015248,461372,437Gross margin

    99,02691,459208,679174,969Operating expenses:Research and development

    8,07722,66018,78727,312Selling, general and administrative

    46,15648,86593,10190,100Settlements and loss contingencies, net

    -(4,068)190,560(4,006)Restructuring costs

    26,986-26,986-Total operating expenses

    81,21967,457329,434113,406Gain on sale of product rights and other

    -146-5,921Operating (loss) income

    17,80724,148(120,755)67,484Interest income

    382273805601Interest expense

    (150)(918)(301)(1,826)Income (loss) from continuing operations before provision
    for income taxes

    18,03923,503(120,251)66,259Provision (benefit) for income taxes

    8,8595,468(20,587)21,798Income (loss) from continuing operations

    9,18018,035(99,664)44,461Discontinued operations:Provision (benefit) for income taxes

    127(360)253(232)(Loss) income from discontinued operations

    (127)360(253)232Net income (loss)

    $9,053$18,395($99,917)$44,693Basic earnings (loss) per share of common stock:Income (loss) from continuing operations

    $0.26$0.53($2.79)$1.31(Loss) income from discontinued operations

    (0.01)0.01(0.01)0.01Net income (loss)  

    $0.25$0.54($2.80)$1.32Diluted earnings (loss) per share of common stock:Income (loss) from continuing operations

    $0.25$0.51($2.79)$1.26(Loss) income from discontinued operations

    (0.00)0.01(0.01)0.01Net income (loss)  

    $0.25$0.52($2.80)$1.27Weighted average number of common shares outstanding:  Basic

    35,98334,11235,74234,021  Diluted

    36,70835,47535,74235,273PAR PHARMACEUTICAL COMPANIES, INC.CONDENSED CONSOLIDATED BALANCE SHEETS (In Thousands, Except Share Data)(Unaudited)June 30,December 31,20112010ASSETSCurrent assets:Cash and cash equivalents$307,011$218,674Available for sale marketable debt securities38,65227,866Accounts receivable, net  122,63095,705Inventories75,35372,580Prepaid expenses and other current assets14,33817,660Deferred income tax assets30,00926,037Income taxes receivable63,32818,605Total current assets651,321477,127Property, plant and equipment, net71,11771,980Intangible assets, net65,57395,467Goodwill63,72963,729Other assets6,6245,441Non-current deferred income tax assets, net56,39569,488Total assets$914,759$783,232LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable$27,381$23,956Payables due to distribution agreement partners50,43525,310Accrued salaries and employee benefits 10,40116,397Accrued government pricing liabilities32,14832,169Accrued legal fees8,6047,084Accrued legal settlements195,400-Accrued expenses and other current liabilities8,2776,674Total current liabilities332,646111,590Long-term liabilities42,81043,198Commitments and contingencies--Stockholders' equity:Common Stock, par value $0.01 per share, authorized 90,000,000 shares; issued39,655,227 and 38,872,663 shares394389Additional paid-in capital391,664373,764Retained earnings229,212329,129Accumulated other comprehensive gain68137Treasury stock, at cost 3,170,185 and 2,970,573 shares(82,035)(74,975)Total stockholders' equity539,303628,444Total liabilities and stockholders' equity$914,759$783,232Reconciliation Between Reported (GAAP); Adjusted Income (Loss) from Continuing Operations and "Cash EPS"(In Thousands, Except Per Share Data)

    (Unaudited)Three Months EndedJune 30,June 30,20112010Income from Continuing Operations$9,180$18,035Restructuring costs

    27,660-Upfront and development milestone payments

    -17,000Litigation settlements and contingencies

    -(4,130)Non-cash interest expense

    -524Sum of adjustments, pre-tax

    $27,660$13,394Estimated tax on adjustments

    (10,234)(5,090)Charge related to valuation of deferred income tax assets

    2,391-Resolution of tax contingencies

    -(3,657)Adjusted Income from Continuing Operations (non-GAAP measure)

    $28,997$22,682Amortization Expense

    3,0133,904Estimated tax impact

    (1,115)(1,484)Amortization Expense, net of tax

    1,8982,420Adjusted Cash basis from Continuing Operations (non-GAAP measure)30,89525,102"Cash EPS" from Continuing Operations (non-GAAP measure)$0.84$0.71Diluted weighted average shares outstanding

    36,70835,475Six Months EndedJune 30,June 30,20112010(Loss) Income from Continuing Operations($99,664)$44,461Litigation settlements and contingencies, pre-tax

    190,560(4,130)Restructuring costs

    27,660-Upfront and development milestone payments

    -17,000Sale of product rights

    -(5,000)Non-cash interest expense

    -1,038Sum of adjustments, pre-tax

    $218,220$8,908Estimated tax on adjustments

    (58,909)(3,385)Charge related to valuation of deferred income tax assets

    2,391-Resolution of tax contingencies

    -(3,657)Adjusted Income from Continuing Operations (non-GAAP measure)

    $62,038$46,327Amortization Expense

    6,1188,154Estimated tax impact

    (2,295)(3,099)Amortization Expense, net of tax

    3,8235,055Adjusted Cash basis from Continuing Operations (non-GAAP measure)65,86151,382"Cash EPS" from Continuing Operations (non-GAAP measure)$1.80$1.46Diluted weighted average shares outstanding

    36,55535,273
    '/>"/>

    SOURCE Par Pharmaceutical Companies, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects?
    2. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of August 2011
    3. Avanir Pharmaceuticals to Present at Two Investor Conferences in August
    4. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
    5. MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX®
    6. Novo Nordisk and Partnership of Ivy Equities, LCOR and Intercontinental RE Corp. Announce Lease Agreement for N.J. Pharmaceutical Companys New U.S. Headquarters
    7. FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
    8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
    9. BGI and GT Life Sciences, Inc. Report Genome Sequence of CHO-K1 and Provide New Insights into Optimization of Biopharmaceutical Protein Production
    10. Though Essential to Pharmaceutical Sales Success, the Use of Health Outcomes Data Often Overlooked by Sales Leaders
    11. Anthera Pharmaceuticals Reports 2011 Second Quarter Financial Results and Operational Update
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/4/2016)... Feb. 4, 2016  Edwards Lifesciences Corporation (NYSE: ... structural heart disease and critical care monitoring, announced today ... (ASR) agreement with Morgan Stanley & Co. LLC to ... is part of the Company,s previously authorized program to ... stock.  --> --> ...
    (Date:2/4/2016)... , Feb. 4, 2016 Wegener ... Global Markets Direct,s, ,Wegener Polyangiitis - Pipeline ... Wegener Polyangiitis,s therapeutic pipeline. This report provides ... Polyangiitis, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ...
    (Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
    Breaking Medicine Technology:
    (Date:2/5/2016)... ... February 05, 2016 , ... Looking for a last-minute Valentine’s Day ... tips of your toes. Foot massage, whether administered by a professional masseuse or a ... The American Board of Multiple Specialties in Podiatry (ABMSP) has taken the ...
    (Date:2/5/2016)... Florida (PRWEB) , ... February 05, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – is poised to once again host, Swirl, A Wine Tasting Event at ...
    (Date:2/5/2016)... ... 05, 2016 , ... The American public tends to feel uncomfortable about drinking ... regular municipal or well water. The recent experience with lead contaminated water in Flint, ... long way toward increasing public acceptance of recycled waste water as drinking water. ...
    (Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one of the ... this weekend’s Big Game. Take the stress out of your party preparation – follow ... happy at every stage of the game. , “The key to hosting a successful ...
    (Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Dr. Justin ... announce their 2nd Annual No Cost Dental Day to individuals in need. The event ... purpose of this No Cost Dental Day is to provide dental care to community ...
    Breaking Medicine News(10 mins):